The number of reactions requiring stock epinephrine tripled over 5 years.
Tag: AAAAI 2016
A LEAP into an Allergic Culture Change
If you felt a sense of trepidation after reading the results of the new LEAP-On follow-up study, you’re not alone.… Read more »
Top Studies from the AAAAI 2016 Allergists’ Meeting
We bring you extensive coverage from the largest gathering of allergists in the world.
Walnut OIT Shows Promise in Small Study
While oral immunotherapy for peanut allergy grabs plenty of headlines, the question is often raised whether the technique will work… Read more »
Needle Length of Auto-Injectors May Need Review for Infants and Toddlers, Study Finds
Epinephrine auto-injectors remain first line of defense for anaphylaxis, and technique can be adjusted to compensate.
Peanut Dust Lingers on Airplane Tray Tables, Restaurant Surfaces
Exposure comes from touching surfaces and then accidentally ingesting peanut, researchers say.
Stock Epi Used in 38% of Anaphylactic Reactions in U.S. Schools
Expanded survey looked at more than 6,500 elementary, middle and high schools.
EAT Study: Feeding 6 Allergens to Babies Safe, But Not Easy
Highly positive results seen for early peanut and egg introduction, but more study needed on other allergens.
Non-steroidal Eczema Drug Shows Promise
Doctors may soon have a new treatment option for patients suffering from mild to moderate eczema after a non-steroidal anti-inflammatory ointment showed promising results in trials.
OIT’s Effects Endure at Low Doses: Stanford Study
In a long-term follow-up study, oral immunotherapy (OIT) patients who were treated for up to five food allergies were able to maintain a high level of desensitization to their allergens, even those taking very low “doses” of their allergens.